Ligand id: 5004

Name: infliximab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: infliximab

1. A-González N, Castrillo A. (2011)
Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.
Biochim. Biophys. Acta, 1812 (8): 982-94. [PMID:21193033]
2. Blair HA, Deeks ED. (2016)
Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
BioDrugs, 30 (5): 469-480. [PMID:27650650]
3. Derzi M, Johnson TR, Shoieb AM, Conlon HD, Sharpe P, Saati A, Koob S, Bolt MW, Lorello LG, McNally J et al.. (2016)
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab).
Adv Ther, 33 (11): 1964-1982. [PMID:27585978]
4. Le J, Vilcek J, Dadonna P, Ghrayeb J, Knight D, Siegel SA. (1997)
Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies.
Patent number: US5656272. Assignee: New York University Medical Center, Centocor, Inc.. Priority date: 18/03/1991. Publication date: 12/08/1997.
5. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL et al.. (1999)
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Gastroenterology, 117 (4): 761-9. [PMID:10500056]
6. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. (1995)
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).
Gastroenterology, 109 (1): 129-35. [PMID:7797011]
7. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B et al.. (2017)
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Ann. Rheum. Dis., 76 (2): 355-363. [PMID:27130908]